(Q37733582)

22 August 2017

1 reference

title

Role of warfarin pharmacogenetic testing in clinical practice (English)

1 reference

22 August 2017

1 reference

Guang-Ming Tan

1

1 reference

22 August 2017

Enoch Wu

series ordinal

2

1 reference

22 August 2017

Yat-Yin Lam

series ordinal

3

1 reference

22 August 2017

Bryan P Yan

series ordinal

4

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

439-448

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

22 August 2017

cites work

1 reference

Pharmacogenetics of oral anticoagulants

21 January 2018

1 reference

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

21 January 2018

1 reference

Genetic and clinical factors relating to warfarin dosing

21 January 2018

1 reference

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

21 January 2018

1 reference

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives

21 January 2018

1 reference

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

Pharmacogenetics and anticoagulant therapy

21 January 2018

1 reference

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis

21 January 2018

1 reference

Biochemistry and molecular biology of the human CYP2C subfamily

21 January 2018

1 reference

Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors

21 January 2018

1 reference

Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements.

21 January 2018

1 reference

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

Biochemical basis of hereditary resistance to warfarin in the rat.

21 January 2018

1 reference

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

21 January 2018

1 reference

Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans

21 January 2018

1 reference

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing

21 January 2018

1 reference

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans

21 January 2018

1 reference

Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement.

21 January 2018

1 reference

Factors affecting the maintenance dose of warfarin

21 January 2018

1 reference

Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.10.8

1 reference

22 August 2017

1 reference